COVI-STIX added to the official government list in MexicoMexican Comisin Federal para la Proteccin contra Riesgos Sanitarios (COFEPRIS), the health regulatory authority for Mexico, has listed COVI-STIX on its official government website list of rapid antigen tests approved for emergency use in Mexico. An
independent study conducted by the government’s epidemiological department, Instituto de Diagnstico y Referencia Epidemiolgicos (InDRE), confirmed the validity of the test in 465 nasopharyngeal samples from symptomatic (7 days or less) or uninfected people, which yielded the following results: Positive Predictive Value
(PPV): 95.77%; Negative Predictive Value
(NPV): 98.42%. Among all the products listed currently, COVI-STIX outperformed for both Sensitivity (91.89%) and Specificity (99.23%).
With today’s approval, Sorrento is able to offer a high quality and affordable diagnostic solution for Mexico. This approval is expected to form the foundation for similar clearances in other Latin American countries, including Brazil, in which Sorrento is currently conducting multiple therapeutic clinical trials.
https://stockhouse.com/news/press-releases/2021/06/02/sorrento-announces-addition-of-covi-stix-tm-covid-19-virus-rapid-antigen